Sign inCreate account

Report workspace tools

NCT00904020COMPLETEDanonymous

A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

Sponsor

Source record

Endo Pharmaceuticals

Phase

Source record

Phase IV

Modality

AI-normalized

small molecule

Target

AI-normalized

Lidoderm (lidocaine patch 5%)

Indication / condition

AI-normalized

Postherpetic Neuralgia

Intervention

Source record

Lidoderm

Source & freshness

Source record

NCT ID

NCT00904020

Original source

ClinicalTrials.gov

Source last updated

Jan 02, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00904020

Title

A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

Sponsor

Endo Pharmaceuticals

Status

COMPLETED

Phase

Phase IV

Condition raw

Postherpetic Neuralgia

Condition normalized

Postherpetic Neuralgia

Modality raw

Postherpetic Neuralgia

Modality normalized

small molecule

Target raw

Lidoderm (lidocaine patch 5%)

Target normalized

Lidoderm (lidocaine patch 5%)

Interventions

Lidoderm

Public preview

Source record

This clinical trial, sponsored by Endo Pharmaceuticals, evaluated the effectiveness and safety of Lidoderm as an add-on treatment for patients experiencing postherpetic neuralgia, diabetic neuropathy, or low back pain while on a gabapentin regimen. The study involved 107 participants and was conducted across multiple sites in the United States.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00904020

Status

COMPLETED

Phase

Phase IV

Sponsor

Endo Pharmaceuticals

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Endo Pharmaceuticals, evaluated the effectiveness and safety of Lidoderm as an add-on treatment for patients experiencing postherpetic neuralgia, diabetic neuropathy, or low back pain while on a gabapentin regimen. The study involved 107 participants and was conducted across multiple sites in the United States.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 02, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00904020

Indication

Postherpetic Neuralgia

Modality

small molecule

Target

Lidoderm (lidocaine patch 5%)

Intervention

Lidoderm

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.